

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/771,440
Filing Date	February 5, 2004
First Named Inventor	Michal DANIELY et al
Art Unit	1643
Examiner Name	DUFFY, BRADLEY
Attorney Docket Number	26003

Filing Date	February 5, 2004
-------------	------------------

First Named Inventor	Michal DANIÉLY et al
----------------------	----------------------

Art Unit	1643
----------	------

Examiner Name	DUFFY, BRADLEY
---------------	----------------

Attorney Docket Number	26003
------------------------	-------

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/771,440
				Filing Date	February 5, 2004
				First Named Inventor	DANIELY Michal et al
				Group Art Unit	1643
				Examiner Name	DUFFY, BRADLEY
Sheet	2	Of	7	Attorney Docket Number	26003
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	4	Bielorai et al. "Combined Analysis of Morphology and FISH in Follow-Up of Minimal Residual Disease (MRD) in A Child With Ph+ Acute Lymphoblastic Leukemia (ALL)", Cancer Genetics and Cytogenetics, 138: 64-68, 2002. Abstract.			
	5	Bielorai et al. "Combined Analysis of Morphology and Fluorescence In Situ Hybridization in Follow-Up of Minimal Residual Disease in A Child With Philadelphia-Positive Acute Lymphoblastic Leukemia", Cancer Genetics and Cytogenetics, 138(1): 64-68, 2002. P.65, r-h Col., § 1, P.67, l-h Col., § 2.			
	6	Bielorai et al. "Follow-Up of Minimal Residual Disease (MRD) in A Child With Ph+ Acute Lymphoblastic Leukemia (ALL) Using Mutiparametric Cell Scanning System", 43th ASH Annual Meeting, Blood, 98(Part 20: 185b, Abstract #4433, 2001. Abstract.			
	7	Bielorai et al. "Full Hematopoietic Engraftment After Allogeneic Peripheral Blood Stem Cell Transplantation Without Conditioning in SCID Patients", 44th ASH Annual Meeting, Blood, 100(Part 1): 409, 2002.			
	8	Bielorai et al. "Multilineage Hematopoietic Engraftment After Allogeneic Peripheral Blood Stem Cell Transplantation Without Conditioning in SCID Patients", Bone Marrow Transplantation, P.1-4, 2004.			
	9	Bielorai et al. "Multilineage Hematopoietic Engraftment in SCID Patients Transplanted With Allogeneic Peripheral Blood Stem Cells Without Preparative Regimen", 29th Annual Meeting of the European Group for Blood and Marrow Transplantation, Istanbul, Turkey, 2003. Abstract.			
	10	Chen et al. "Targeting of Abnormal Plasma Cells With Image Analysis May Significantly Improve the Abnormal Detection Rate Determined by FISH in Multiple Myeloma", 2004 Annual Meeting of the United States and Canadian Academy of Pathology, Vancouver, Canada, Abstract #1487, 2004. Abstract.			
	11	Daniely et al. "Combined Analysis of Morphology and FISH for the Monitoring of Bladder Cancer", Annales de Genetique, 46(2-3): 153, 2003. & Fourth European Cytogenetics Conference, Bologna, Italy, 2003.			
	12	Daniely et al. "Combined Analysis of Morphology and Fluorescence in Situ Hybridization Significantly Increases Accuracy of Bladder Cancer Detection in Voided Urine Samples", Urology, 66: 1354-1359, 2005.			
	13	Debes-Marun et al. "Circulating B Lymphocytes From Patients With Multiple Myeloma Harbour T(4;14) Translocations and Chromosome 13 Deletions. Session Type: Oral Session", Blood, 106(11): Abstract #500, 2005.			
Examiner Signature					Date Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/771,440
				Filing Date	05-Feb-2004
				First Named Inventor	DANIELY Michal et al
				Art Unit	1643
				Examiner Name	DUFFY, BRADLEY
Sheet	3	Of	7	Attorney Docket Number	26003
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	14	Hardan et al. "Detection of 13q Deletion in the Bone Marrow Cells of Patients With Multiple Myeloma Using Combined Morphological and FISH Analysis", Blood, 100(11): 392a, Abstract# 1522, 2002. & 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, USA, 2002.			
	15	Hardan et al. "Determination of Chromosome 13 Status in Bone Marrow Cells of Patients With Multiple Myeloma Using Combined Morphologic and Fluorescence In Situ Hybridization Analysis", Experimental Hematology, 32: 254-260, 2004.			
	16	Inoue et al. "Chromosomal Numerical Aberrations of Exfoliated Cells in the Urine Detected by Fluorescence In Situ Hybridization: Clinical Implication for the Detection of Bladder Cancer", Urological Research, 28(1): 57-61, 2000. P.58, § 1, Fig.1, Table 2.			
	17	Kaplinsky et al. "Combined Analysis of Morphology and FISH Using the Duet™ Automatic Cells Scanning System, Increases the Accuracy of Leukemia Diagnosis", The Hematology Journal, 3: 201, Poster No.0668, 2002. Abstract.			
	18	Kaplinsky et al. "Haemopoietic Growth Factor. Tetraploid Myeloid Cells in Donors of Peripheral Blood Stem Cells Treated With RhG-CSF", Bone Marrow Transplantation, 32: 31-34, 2003.			
	19	Kaplinsky et al. "Increased Accuracy of Leukemia Diagnosis by Combined Analysis of Morphology and FISH Using the Duet™ Automatic Cell Scanning System", European Journal of Human Genetics, 10(Suppl.1): 90, 2002. & European Human Genetics Conference 2002 in Conjunction With the European Meeting on Psychological ASP, Strasbourg, France, 2002.			
	20	Kaplinsky et al. "Minimal Residual Disease and Chimerism Detection After Bone-Marrow Transplantation Using An Automatic Cell Scanning System", 43rd ASH Annual Meeting, Blood, 98(Part 2): 348b, 2001. Abstract.			
	21	Kneller et al. "Acquisition of Ph-Chromosome With Minor BCR/ABL Fusion as Second Clonal Event Following T-MDS With Chromosome 7 Abnormalities in A Patient Treated for Hodgkin Disease", Cancer Genetic and Cytogenetic, 199: 58-62, 2005.			
	22	Knudson et al. "Comparison of the BioView Duet Automated Dot Counting System to Technologist Scoring Using the D-FISH Strategy in Patients With CML", Association of Genetic Technology, Atlanta, GA, USA. Abstract.			
Examiner Signature				Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/771,440	
				Filing Date	05-Feb-2004	
				First Named Inventor	DANIELY Michal et al	
				Art Unit	1643	
				Examiner Name	DUFFY, BRADLEY	
Sheet	4	Of	7	Attorney Docket Number		26003
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
	23	Lev et al. "Automatic Scanning of Interphase FISH for Prenatal Diagnosis in Uncultured Amniocytes", Genetic Testing, 9(1): 41-47, 2005.				
	24	Malingier et al. "Automatic Scanning of Interphase FISH for Prenatal Diagnosis in Uncultured Amniocytes", Annales de Génétiques, International Journal of Human and Medical Genetics, 46(13.27): 323, 2003. Abstract.				
	25	McCormick et al. "HER2 Assessment By Immunohistochemical Analysis and Fluorescence In Situ Hybridization", American Journal of Clinical Pathology, 117: 935-943, 2002. See Abstract.				
	26	Raani et al. "Philadelphia-Chromosome-Positive T-Lymphoblastic Leukemia: Acute Leukemia or Chronic Myelogenous Leukemia Blastic Crisis", Acta Haematologica, 113: 181-189, 2005.				
	27	Rosenberg et al. "Major Mutations in Calf-1 and Calf-2 Domains of Glycoprotein IIb in Patients With Glanzmann Thrombasthenia Enable GPIIb/IIIa Complex Formation, But Impair Its Transport From the Endoplasmic Reticulum to the Golgi Apparatus", Blood, 101(12): 4808- 4816, 2003.				
	28	Rothman et al. "A New AML1 Deletion in Pediatric TEL/AML1 Positive ALL Patients: Detection and Monitoring of Minimal Residual Disease by FISH Analysis", 38th Annual Congress of the Israeli Society for Clinical Laboratory Sciences, Tel Aviv, IL, 2004. Abstract.				
	29	Rothman et al. "Additional Cytogenetic Events in Pediatric Acute Lymphoblastic Leukemia Patients With T(12:12): Deletion of the Region 3' to the AML1 Breakpoint (Intron 2) and Subsequent Deletion of the Normal TEL Allele", Annales de Génétiques, International Journal of Human and Medical Genetics, 46(2.68): 139, 2003. Abstract.				
	30	Rothman et al. "Co-Existence of Multiple Subclones in TEL-AML1 at Diagnosis of Acute Lymphoblastic Leukaemia in Association With Submicroscopic Deletion of AML1", British Journal of Haematology, 129: 491-498, 2005.				
	31	Rothman et al. "Combined Morphological Immunophenotypic and Molecular Cytogenetic Analysis of Minimal Residual Disease in Acute Leukemias for Testing Chimerism After Allogeneic Bone Marrow Transplantation", ILMAR Conference, Tel Aviv, IL, Poster Award, 2003. Abstract.				
Examiner Signature					Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/771,440
				Filing Date	05-Feb-2004
				First Named Inventor	DANIELY Michal et al
				Art Unit	1643
				Examiner Name	DUFFY, BRADLEY
Sheet	5	Of	7	Attorney Docket Number	26003
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	32	Rothman et al. "Detection of 13q Deletion in the Bone Marrow Cells of Patients With Multiple Myeloma Using Combined Morphological and FISH Analysis", The Annual Meeting of the Genetics Society of Israel, Challenges in Genetics in the 21st Century, Tel Aviv, IL, Poster P5, 2003. Abstract.			
	33	Rothman et al. "Improved Detection of Chromosome 13 Status in Multiple Myeloma Patients With Modern Technologies: Combined Morphological and FISH Analysis", ILMAR Conference, Tel Aviv, IL, Oral Presentation, 2003. abstract.			
	34	Shimoni et al. "Chimerism Detection After Bone-Marrow Transplantation, Using Combined Morphological and Cytogenetical Analysis", The Hematology Journal, 3: 201, Poster 0669, 2002. Abstract.			
	35	Shimoni et al. "Chimerism Testing and Detection of Minimal Residual Disease in A Patient With Ph+ Acute Lymphoblastic Leukemia After Bone Marrow Transplantation Using Multiparametric Cell Scanning System", BioView Ltd. Israel. Abstract.			
	36	Shimoni et al. "Detection of host Blasts But Not Mature Hematopoietic Cells Among Minute Host Populations Remaining after Allogeneic Transplantation, Using Combined Morphological and Cytogenetic Analysis, Predicts Imminent Relapse", 44th ASH Annual Meeting, Blood, 100(16/Part 2): 631a, Abstract #2485, 2002. Abstract.			
	37	Slovak et al. "Fluorescence In Situ Hybridization (FISH) Targeting Plasma Cells Improves the Detection of Multiple Myeloma: Phenotype/Genotype Correlation in Residual Disease Detection", The American Society of Human Genetic Society Conference, Toronto, Canada, Abstract #239, 2004. Abstract.			
	38	Slovak et al. "Targeting Plasma Cells Improves Detection of Cytogenetic Aberrations in Multiple Myeloma: Phenotype/Genotype Fluorescence in Situ Hybridization", Cancer Genetics and Cytogenetics, 158: 99-109, 2005.			
	39	Strassburger et al. "Computerized Cell Scanning in the Classification of Testicular Germ Cells in Non-Obstructive Azoospermic Patients", Annual Meeting of the Israel Society of Fertility, Tel Aviv, IL, Abstract #25, 2005. Abstract.			
	40	Strassburger et al. "Morphology and Fluorescence In Situ Hybridization on the Same Sperm Cell Controlled by Computerised Cell Scanning System", 19th Annual Meeting of the European Society of Human Reproduction and Embryology, Madrid, ESHRE 2003, 2003. Abstract.			
Examiner Signature					Date Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/771,440
				Filing Date	05-Feb-2004
				First Named Inventor	DANIELY Michal et al
				Art Unit	1643
				Examiner Name	DUFFY, BRADLEY
Sheet	6	Of	7	Attorney Docket Number	26003
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	41	Strassburger et al. "Morphology Assessment and Fluorescence In-Situ Hybridization of the Same Spermatozoon Using a Computerized Cell-Scanning System", Human Reproduction, 22(1): 201-209, 2007.			
	42	Sulcova et al. "Computer-Assisted Fluorescence In Situ Hybridization (FISH) Analysis for Bladder Cancer Recurrence", 30th Annual Meeting of American Association of Genetic Technologists, Kansas City, Missouri, USA, Abstract #47, 2005. Abstract.			
	43	Trakhtenbrot et al. "Clinical Significance of the Combined Morphological, Immunophenotypic and Molecular Cytogenetic Analysis of Hematological Malignancies", Annales de Génétique, International Journal of Human and Medical Genetics, 46(2.80): 145, 2003. Abstract.			
	44	Trakhtenbrot et al. "Combined Morphological and Fish Analysis of Aneuploidy in Oral Premalignancy", 10th European Workshop of Molecular Cytogenetics in Human Solid Tumours, La Grande Motte, France, P.31, 2006. Abstract.			
	45	Trakhtenbrot et al. "Combined Morphological, Immunophenotypic and Molecular Cytogenetic Analysis of Minimal Residual Disease in Acute Leukemias for Testing Chimerism After Allogeneic Bone Marrow Transplantation", The 37th Annual Meeting of the Genetic Society of Israel Aviv, IL, Poster P6, 2003. Abstract., Tel			
	46	Trakhtenbrot et al. "Detection of the Full Hematopoietic Engraftment After Allogeneic Peripheral Stem Cell Transplantation Without Conditioning in SCID Patients Using Combined Morphology, Immunophenotype and Fluorescence In Situ Hybridization (FISH)", 38th Annual Congress of the Israeli Society for Clinical Laboratory Sciences, Tel Aviv, IL, 2004. Abstract.			
	47	Trakhtenbrot et al. "The Multiparametric Scanning System for Evaluation of Minimal Residual Disease in Hematological Malignancies", Acta Haematologica, 112: 24-29, 2004.			
	48	Van Agthovan et al. Differential Expression Of Estrogen, Progesterone, And Epidermal Growth Factor Receptors In Normal, Benign, And Dual Staining Immunohistochemistry", Amereican Journal of Pathology, 144(6): 1238-1246, 1994.			
	49	Vasir et al. "Dendritic Cell Chimersim and Function Following Nonmyeloablative Allogeneic Stem Cell Transplantation", 45th ASH Annual Meeting , Blood, 102(11/Part 1): 695a, Abstract. #2575, 2003. Abstract.			
Examiner Signature					Date Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*